Sort   by:  
 Page size 
UnknownDiagnostic performance of plasma p-tau217 and Aβ42/40 biomarkers in the outpatient memory clinic.
Not available
S-EPMC12142430 | biostudies-literature
TranscriptomicsValidation of a genomic classifier that predicts metastasis following radical prostatectomy in at risk patient population
Purpose: Patients with locally advanced prostate cancer after radical prostatectomy are candidates for secondary therapy. However, this higher risk population is heterogeneous. Many cases do not metastasize even when conservatively managed. Given the limited specificity of pathological features to p...
ORGANISM(S): Homo sapiens 
2014-11-13 | E-GEOD-62116 | biostudies-arrayexpress
UnknownMulti-omics driven predictions of response to acute phase combination antidepressant therapy: a machine learning approach with cross-trial replication.
Not available
S-EPMC8497535 | biostudies-literature
UnknownMyD88 and TLR4 Expression in Epithelial Ovarian Cancer.
Not available
S-EPMC5870793 | biostudies-literature
UnknownPrognostic risk score for patients with relapsed or refractory chronic lymphocytic leukaemia treated with targeted therapies or chemoimmunotherapy: a retrospective, pooled cohort study with external validations.
Not available
S-EPMC6620111 | biostudies-literature
UnknownA simplified scoring system in de novo follicular lymphoma treated initially with immunochemotherapy.
Not available
S-EPMC6034646 | biostudies-literature
UnknownA Systematic Literature Review of Coordinated Care in Cardiovascular-Kidney-Metabolic Conditions.
Not available
S-EPMC12657295 | biostudies-literature
UnknownFour-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31.
Not available
S-EPMC3164242 | biostudies-literature
UnknownRelapsed/Refractory International Prognostic Index (R/R-IPI): An international prognostic calculator for relapsed/refractory diffuse large B-cell lymphoma.
Not available
S-EPMC8763015 | biostudies-literature
GenomicPROstate Cancer Medically Optimized Genome Enhanced ThErapy (PROMOTE)

The Prostate Cancer Medically Optimized Genome-Enhanced Therapy (PROMOTE) study uses genetic clues in castration-resistant prostate cancer that may identify an individualized treatment approach for men with the disease.

Understanding the molecular biology behind castration-resistant prosta...

phs001141 | dbGaP
Sort   by:  
 Page size